Asia-Pacific Cardiac Biomarker Market Report 2021: By Key Players, Application, Type, Market Share, Forecast to 2027

Asia-Pacific cardiac biomarker market is estimated to grow significantly at a CAGR of around 7.1% during the forecast period. The Asia-Pacific has a potential market in cardiac biomarkers due to various factors such as rising healthcare spending, improving infrastructure& economy, and rising standards of living. China, India, Japan, Australia, Korea, and Taiwan are the key regions growing at a significant rate in the region. The healthcare systems in the region are improving significantly and expected to contribute to the cardiac biomarker market. The reason behind the potetial market is the support from government organizations and funding and investment in the cardiac biomarker research. In addition, the presence of key players contributes to the market growth of the cardiac biomarker in Asia-Pacific.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-cardiac-biomarker-market

The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the Asia-Pacific cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.  

Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/asia-pacific-cardiac-biomarker-market

The companies which are contributing to the growth of the Asia-Pacific cardiac biomarker market include Abbott Laboratories, BioMérieux S.A., Cisbio Bioassays SAS, Danaher Corp., F. Hoffmann-La Roche AG, HyTest Ltd, Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market. 

Market Segmentation

By Type 

  • Creatine kinase (CK-MB)
  • Troponins(T,I)
  • Myoglobin
  • Natriuretic peptides (BNP & NT-PROBNP)
  • Ischemia modified albumin
  • Others

By Application

  • Myocardial infraction
  • Congestive heart failure
  • Acute coronary syndrome
  • Atherosclerosis
  • Others

By Location of Testing

  • Laboratory testing
  • Point of care testing
  1. Regional Analysis
  • China
  • India
  • Japan 
  • Rest of Asia-Pacific

Company Profiles

  • Abbott Laboratories 
  • BioMérieux S.A. 
  • Cisbio Bioassays SAS 
  • Danaher Corp.
  • Hoffmann-La Roche AG
  • HyTest Ltd. 
  • Merck KGaA
  • Randox Laboratories Ltd. 
  • Siemens Healthcare GmbH 
  • Thermo Fisher Scientific Inc.

(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)